Related Experiment Videos
[History and significance of sensitivity test of anticancer drugs]
Abstract:
Many anticancer drugs are now available for clinical use. Unfortunately, most are extremely toxic to normal tissue. Use of one or more toxic drugs inactive against the given patient's own cancer may not only deny the patients the benefit of active therapy but may actually make the patient's cancer grow faster. The need for adjuvant chemotherapy can scarcely be doubted. However, distant metastases may be present at the time of primary surgery in many cases. Some form of generalized therapy like drug therapy or immunotherapy must therefore be used to supplement our local form of treatment such as surgery and radiation therapy for cancer. Already the dangers of cancer chemotherapy are reported as adverse effect, not only in the case of advanced cancer patients, but, that of post operative adjuvant chemotherapy. Therefore, predictive assays analogous to antibiotic sensitivity tests are needed to rule out inactive drugs and select active drugs with least toxicity. The treatment of patients with cancer according to the result of tests of sensitivity of cancer cells to anticancer drugs has been introduced many years ago. The examination of the sensitivity is carried out on explanted tumor cells by two different methodical approaches-observation of the cytotoxic effect of the preparation tested to the growth of the tissue culture of the tumor examined, and a short-term examination with the indication of the effect of anticancer drugs according to the decreased utilization or incorporation of the precussors of the synthesis of proteins, RNA and DNA labeled with radioisotopes, or according to the release of enzymes from tumor cells damaged by an efficient anticancer drug. However, clinicians know that there are many disagreements between the sensitivity test and clinical results. Each sensitivity test has its limitation and problems for resolution. Research toward the goal of the sensitivity test is to divise more appropriate method which is simple prompt and precise for drug selection.
Insights
Predictive assays for anticancer drug sensitivity are crucial for selecting effective treatments and minimizing toxicity in cancer patients. Current methods show discrepancies with clinical outcomes, necessitating research for more precise and prompt drug selection tools.
Area of Science:
- Oncology
- Pharmacology
- Biotechnology
Context:
- Anticancer drugs are vital but often toxic to normal tissues, potentially accelerating cancer growth if ineffective.
- Adjuvant chemotherapy and generalized therapies like immunotherapy are necessary due to potential distant metastases at diagnosis.
- Adverse effects of cancer chemotherapy are reported in both advanced and post-operative adjuvant settings.
Purpose:
- To highlight the need for predictive assays, similar to antibiotic sensitivity tests, to guide anticancer drug selection.
- To review existing methods for assessing cancer cell sensitivity to drugs, including tissue culture and radioisotope-based assays.
- To address the limitations and clinical discrepancies associated with current cancer drug sensitivity tests.
Summary:
- Existing methods for determining anticancer drug sensitivity involve observing cytotoxic effects on tumor tissue cultures or measuring the impact on precursor synthesis (DNA, RNA, protein) using radioisotopes.
- Short-term assays also assess drug efficacy by monitoring the release of enzymes from damaged tumor cells.
- Despite these approaches, significant disagreements between in vitro sensitivity tests and actual clinical results persist, indicating a need for improved methodologies.
Impact:
- The development of more accurate, simple, and rapid sensitivity tests is essential for optimizing cancer treatment selection.
- Improved predictive assays can help clinicians choose active anticancer drugs while minimizing toxicity and avoiding ineffective therapies.
- Advancing drug sensitivity testing can lead to more personalized and effective cancer chemotherapy regimens, improving patient outcomes.